Favipiravir
- Generic Name
- Favipiravir
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF
- Conditions
- Crimean-Congo Hemorrhagic Fever
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Liverpool School of Tropical Medicine
- Target Recruit Count
- 378
- Registration Number
- NCT06860334
Assessing Antiviral Treatments in Early Symptomatic RSV
- Conditions
- Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 1000
- Registration Number
- NCT06488300
- Locations
- 🇹🇭
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
- Conditions
- Lassa Fever
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Irrua Specialist Teaching Hospital
- Target Recruit Count
- 1755
- Registration Number
- NCT06212336
Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers
- Conditions
- Infectious DiseasePharmacology
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Target Recruit Count
- 39
- Registration Number
- NCT06024421
- Locations
- 🇫🇷
University Hospital Bichat - Claude Bernard, Paris, France
UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Liverpool School of Tropical Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT05940545
- Locations
- 🇹🇷
Ankara Oncology Training and Research Center, Ankara, Yenimahalle, Turkey
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- Conditions
- InfluenzaInfluenza, Human
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3000
- Registration Number
- NCT05648448
- Locations
- 🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Lao People's Democratic Republic
🇳🇵Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Mansoura University Hospital
- Target Recruit Count
- 265
- Registration Number
- NCT05502081
- Locations
- 🇪🇬
El-gomhoria St, Mansoura, El-dkhalia, Egypt
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
- Conditions
- COVID-19 Respiratory InfectionFLUCold; InfluenzaBacterial PneumoniaCOVID-19 Pneumonia
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- RAAS Nutritionals, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT05417997
- Locations
- 🇹🇷
Kayseri City Hospital, Kayseri, Kayseri Province, Turkey
Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
- Conditions
- Moderate to Severe COVID-19
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT05279235
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
🇺🇿Specialized lnfectious Diseases Hospital No2 of Zangiota District, Tashkent, Tashkent Province, Uzbekistan
Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Promomed, LLC
- Target Recruit Count
- 217
- Registration Number
- NCT05185284
- Locations
- 🇷🇺
Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation
🇷🇺Smolensk clinical hospital №1, Smolensk, Russian Federation
🇷🇺State Clinical Hospital №50, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.